Standard BioTools Q3 revenue $45M, net loss improves 34.6% YoY; reaffirms FY2024 outlook

STANDARD BIOTOOLS INC.

2024-Q3 EPS reported -$0.44 revenue$127,714,000

Q3 2024 revenue $45.0M (-5% YoY pro forma); net loss $26.9M improved from $41.2M loss YoY.
Adjusted EBITDA loss $14.2M vs $28.2M loss YoY, a 49.6% improvement; merger synergies $80M on track for 2025.
Consumables revenue up 13% to $14.0M; Instruments down 42% to $5.6M due to capital constraints, especially China.
FY2024 revenue guidance reaffirmed at $170M-$175M; path to adjusted EBITDA break-even in 2026.
Cash and short-term investments $367.6M; gross margin 51.7% (42.5% YoY), non-GAAP gross margin 56.9%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.